Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03253211|
Recruitment Status : Not yet recruiting
First Posted : August 17, 2017
Last Update Posted : September 14, 2017
|Condition or disease|
|Sickle Cell Disease|
The investigators will achieve the goals stated above through three aims.
- Examine the effects of decision support tools on study outcomes during the 12 months prior to project start and across the 3.5 years of the project in NC and SC. The investigators will also determine which patient and practice level characteristics predict study outcomes.
- Evaluate individual provider-reported awareness, use and preference of health maintenance tables and algorithms amongst PCPs and ED providers in NC and SC at project start and yearly across the project. Additionally, the investigators will explore patient reported awareness of and satisfaction with co-management model of care in NC and SC.
- The investigators will conduct an exploratory cost analysis of the dissemination and implementation of the SCD co-management model and its effect on healthcare resource utilization.
|Study Type :||Observational|
|Estimated Enrollment :||2270 participants|
|Official Title:||Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina|
|Estimated Study Start Date :||September 1, 2018|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||September 2020|
North Carolina and South Carolina
Primary care and emergency department clinicians
Baseline, year 2, year 3
- HU refills [ Time Frame: 12 months ]number of hydroxyurea prescription refills per patient
- Co-management visits [ Time Frame: 12 months ]number of co-management visits per patient
- ED visits [ Time Frame: 12 months ]number of visits to the emergency department per patient
- In-patient hospitalizations [ Time Frame: 12 months ]number of in-patient hospitalizations per patient
- Re-admission to hospital within 30 days [ Time Frame: 12 months ]number of re-admissions per patient over the course of one year
- Primary care visits [ Time Frame: 12 months ]number of visits to primary care provider per patient
- Specialty visits [ Time Frame: 12 months ]number of specialty care visits per patient
- Transcranial doppler screening [ Time Frame: 12 months ]number of transcranial doppler screenings per patient
- Opioid prescription fills [ Time Frame: 12 months ]number of opioid prescription fill days per patient
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03253211
|Contact: Paula Tanabe, PhD||(919) firstname.lastname@example.org|
|Contact: Nirmish Shah, MD||(919) email@example.com|
|Principal Investigator:||Paula Tanabe, PhD||Duke University|